Cav1/EREG/YAP Axis in the Treatment Resistance of Cav1-Expressing Head and Neck Squamous Cell Carcinoma

Cav1/EREG/YAP Axis in the Treatment Resistance of Cav1-Expressing Head and Neck Squamous Cell Carcinoma

The EGFR-targeting antibody cetuximab (CTX) combined with radiotherapy is the only targeted therapy that has been proven effective for the treatment of locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Recurrence arises in 50% of patients with HNSCC in the years following treatment....

Full description

Bibliographic Details
Main Authors: Mickaël Burgy, Aude Jehl, Ombline Conrad, Sophie Foppolo, Véronique Bruban, Nelly Etienne-Selloum, Alain C. Jung, Murielle Masson, Christine Macabre, Sonia Ledrappier, Hélène Burckel, Carole Mura, Georges Noël, Christian Borel, François Fasquelle, Mihaela-Alina Onea, Marie-Pierre Chenard, Alicia Thiéry, Monique Dontenwill, Sophie Martin
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
head and neck cancer
biomarkers
EGFR therapy
Online Access:https://www.mdpi.com/2072-6694/13/12/3038

Internet

https://www.mdpi.com/2072-6694/13/12/3038

Similar Items